Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1150 MG double-blinded secukinumab
(D09967)		----1件: 271 💬
2150 MG OPEN-label secukinumab
(D09967)		----1件: 271 💬
3300 MG double-blinded secukinumab
(D09967)		----1件: 271 💬
4Secukinumab
(D09967)		1件: Secukinumab1件: Secukinumab (D09967) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
5Secukinumab 150 MG
(D09967)		1件: Secukinumab1件: Secukinumab (D09967) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 41 💬
6Secukinumab 150 MG (2 injections PER dose
(D09967)		1件: Secukinumab1件: Secukinumab (D09967) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 269 💬
7Secukinumab 150 MG/1 ML solution FOR injection
(D09967)		1件: Secukinumab1件: Secukinumab (D09967) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬2件: 37, 271 💬
8Secukinumab 150 MG/ML
(D09967)		1件: Secukinumab1件: Secukinumab (D09967) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
9Secukinumab 150MG
(D09967)		1件: Secukinumab1件: Secukinumab (D09967) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 37 💬
10Secukinumab 300 MG
(D09967)		1件: Secukinumab1件: Secukinumab (D09967) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 41 💬
11Secukinumab 300MG
(D09967)		1件: Secukinumab1件: Secukinumab (D09967) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 37 💬
12Secukinumab 75 MG/0.5 ML solution FOR injection
(D09967)		1件: Secukinumab1件: Secukinumab (D09967) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
13Secukinumab injection
(D09967)		1件: Secukinumab1件: Secukinumab (D09967) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 160 💬